Literature DB >> 18173970

Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.

Jennifer B Green1, Mark N Feinglos.   

Abstract

Diabetes mellitus and obesity have become increasingly prevalent problems worldwide. Unfortunately, with traditionally prescribed glucose-lowering medications most individuals with diagnosed diabetes do not achieve and maintain adequate glycemic control over time; it may be even more challenging to lower blood glucose to an appropriate level without inducing a significant associated weight gain. Exenatide and rimonabant are recently developed agents that have demonstrated benefit in both glucose lowering and reduction of body weight. These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173970     DOI: 10.1007/s11892-007-0060-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  44 in total

1.  Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

Authors:  Kishore M Gadde; David B Allison
Journal:  Circulation       Date:  2006-08-29       Impact factor: 29.690

Review 2.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

3.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 4.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

Authors:  Michael A Nauck; Juris J Meier
Journal:  Regul Pept       Date:  2005-06-15

Review 5.  Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.

Authors:  Mauro A M Carai; Giancarlo Colombo; Paola Maccioni; Gian Luigi Gessa
Journal:  CNS Drug Rev       Date:  2006

Review 6.  Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.

Authors:  Stephen C Woods
Journal:  Am J Med       Date:  2007-03       Impact factor: 4.965

7.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

8.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 9.  Rimonabant--a selective CB1 antagonist.

Authors:  Steven Thomas Boyd; Brad Allen Fremming
Journal:  Ann Pharmacother       Date:  2005-03-08       Impact factor: 3.154

10.  Exenatide.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more
  3 in total

1.  Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors:  Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal:  Clin Med Ther       Date:  2009-08-27

2.  Exenatide: a new promising antidiabetic agent.

Authors:  C K Chakraborti
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

3.  Incretin effects on β-cell function, replication, and mass: the human perspective.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.